NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

CMRX

Chimerix Inc

Apr 17 • 04:00PM ET

8.54

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA REGN AMGN GILD VRTX PFE BNTX BIIB NVAX SRPT

| Held by: VTI VXF ARB EVNT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.99	Insider Own	15.43%	Shs Outstand	92.21M	Perf Week	0.12%
Market Cap	801.08M	Forward P/E	-	EPS next Y	-0.80	Insider Trans	-0.14%	Shs Float	79.33M	Perf Month	0.71%
Income	-88.39M	PEG	-	EPS next Q	-0.27	Inst Own	43.93%	Short Float	4.27%	Perf Quarter	133.33%
Sales	0.21M	P/S	3814.67	EPS this Y	12.63%	Inst Trans	23.07%	Short Ratio	0.84	Perf Half Y	905.65%
Book/sh	1.32	P/B	6.47	EPS next Y	8.09%	ROA	-49.27%	Short Interest	3.39M	Perf Year	828.16%
Cash/sh	1.40	P/C	6.09	EPS next 5Y	55.04%	ROE	-56.17%	52W Range	0.75 - 8.55	Perf YTD	145.40%
Dividend Est.	-	P/FCF	-	EPS past 5Y	13.44%	ROI	-72.37%	52W High	-0.12%	Beta	-0.61
Dividend TTM	-	Quick Ratio	5.69	Sales past 5Y	271.06%	Gross Margin	-	52W Low	1038.67%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	5.69	EPS Y/Y TTM	-6.31%	Oper. Margin	-45550.47%	RSI (14)	80.86	Volatility	0.19% 0.28%
Employees	81	Debt/Eq	0.01	Sales Y/Y TTM	-34.57%	Profit Margin	-41691.98%	Recom	3.00	Target Price	8.54
Option/Short	Yes / No	LT Debt/Eq	0.00	EPS Q/Q	-24.47%	Payout	-	Rel Volume	0.00	Prev Close	8.54
Sales Surprise	-81.65%	EPS Surprise	3.85%	Sales Q/Q	1325.00%	Earnings	Mar 21 BMO	Avg Volume	4.05M	Price	8.54
SMA20	0.23%	SMA50	19.84%	SMA200	190.25%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
May-23-23	Initiated	Robert W. Baird	Outperform	$7
Sep-07-22	Initiated	CapitalOne	Overweight	$7
Apr-29-21	Initiated	Maxim Group	Buy	$20
Apr-23-21	Resumed	Cowen	Outperform	$10 → $18
Mar-31-21	Initiated	Wedbush	Outperform	$21
Mar-31-21	Initiated	Jefferies	Buy	$21
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Feb-02-18	Initiated	H.C. Wainwright	Buy	$10
Aug-09-16	Reiterated	FBR Capital	Mkt Perform	$9 → $8
Feb-23-16	Reiterated	FBR Capital	Mkt Perform	$14 → $10
Feb-23-16	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Feb-23-16	Downgrade	Barclays	Overweight → Equal Weight	$12 → $6
Feb-22-16	Downgrade	Citigroup	Buy → Neutral
Dec-29-15	Downgrade	JP Morgan	Overweight → Neutral	$65 → $15
Dec-28-15	Reiterated	Piper Jaffray	Overweight	$63 → $10
Dec-28-15	Downgrade	FBR Capital	Outperform → Mkt Perform	$73 → $14
Dec-17-15	Initiated	UBS	Buy	$55
Oct-05-15	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-03-15	Initiated	Citigroup	Buy
Aug-18-15	Initiated	FBR Capital	Outperform	$73

Show Previous Ratings

Apr-17-25 07:49AM	Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025? (Zacks)
Apr-12-25 11:00AM	Goldman Sachs, J&J, To Report Earnings As Investors Watch Out For Retail Sales Data (Seeking Alpha)
Apr-09-25 08:45AM	JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell? (Zacks)
Apr-01-25 12:52PM	Is Chimerix Inc. (CMRX) the Best Performing NASDAQ Stock So Far in 2025? (Insider Monkey)
Mar-31-25 02:34PM	Biotech Stocks Q1 2025 Recap: Winners And Underperformers (Seeking Alpha)
10:33AM	Loading…
Mar-26-25 10:33AM	Chimerix Inc. (NASDAQ:CMRX) Amazing Performance So Far In 2025 (InsiderMonkey)
Mar-21-25 06:06AM	Chimerix: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Chimerix Reports Fourth Quarter and Year End 2024 Financial Results (GlobeNewswire)
Mar-09-25 06:09PM	Why Chimerix, Inc. (CMRX) Soared Last Week (Insider Monkey)
Mar-07-25 04:01PM	Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-06-25 10:01AM	Chimerix downgraded to Neutral from Buy at H.C. Wainwright (TipRanks)
Mar-05-25 01:03PM	Jazz Pharmaceuticals bids for Chimerix in $935m deal (Pharmaceutical Technology) +70.56%
07:00AM	Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio (PR Newswire)
06:53AM	Jazz expands in oncology with $935M deal for Chimerix (BioPharma Dive)
Feb-18-25 04:01PM	Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.27% +5.18%
07:00AM	Loading…
07:00AM	Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma (GlobeNewswire)
Jan-29-25 04:15PM	Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium (GlobeNewswire)
Jan-24-25 04:01PM	Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-13-25 04:21PM	Heres Why Chimerix, Inc. (CMRX) Is Skyrocketing (Insider Monkey)
07:00AM	Chimerix to Speak Today at The White House Cancer Moonshot Forum (GlobeNewswire)
Dec-30-24 07:00AM	Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma (GlobeNewswire)
Dec-10-24 01:51PM	Chimerix Soars 220% on FDA Filing Plans for Lifesaving Brain Cancer Therapy (GuruFocus.com) +219.08%
09:39AM	Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday? (Benzinga)
Dec-09-24 04:01PM	Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End (GlobeNewswire)
Dec-06-24 04:01PM	Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-11-24 07:00AM	Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting (GlobeNewswire) +5.05%
Nov-08-24 02:22AM	Q3 2024 Chimerix Inc Earnings Call (Thomson Reuters StreetEvents) +5.87%
02:12AM	Chimerix Inc (CMRX) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid Financial ... (GuruFocus.com)
Nov-07-24 08:35AM	Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -7.42%
07:35AM	Chimerix: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Loading…
07:00AM	Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update (GlobeNewswire)
Nov-06-24 07:50AM	Chimerix Inc (CMRX) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Nov-01-24 07:00AM	Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024 (GlobeNewswire)
Oct-18-24 04:31PM	Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-24 07:00AM	Chimerix to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -7.01%
Aug-30-24 04:05PM	Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-14-24 06:14AM	Q2 2024 Chimerix Inc Earnings Call (Thomson Reuters StreetEvents) +9.47%
Aug-13-24 08:15AM	Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -6.16%
07:14AM	Chimerix: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Chimerix Reports Second Quarter 2024 Financial Results and Provides Operational Update (GlobeNewswire)
Aug-06-24 08:45AM	Rapid Advancements of Innovative Antiviral COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market (GlobeNewswire)
07:00AM	Chimerix to Report Second Quarter 2024 Financial Results and Provide an Operational Update on August 13, 2024 (GlobeNewswire)
Jul-05-24 04:05PM	Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-24 07:00AM	Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference (GlobeNewswire)
May-02-24 10:23AM	Chimerix, Inc. (NASDAQ:CMRX) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:09AM	Chimerix Inc (CMRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ... (GuruFocus.com)
May-01-24 11:58PM	Q1 2024 Chimerix Inc Earnings Call (Thomson Reuters StreetEvents)
12:54PM	CMRX Stock Earnings: Chimerix Misses EPS for Q1 2024 (InvestorPlace)
07:33AM	Chimerix: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update (GlobeNewswire)
Apr-24-24 07:00AM	Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024 (GlobeNewswire)
Apr-16-24 04:05PM	Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-21-24 07:00AM	Chimerix Appoints Marc D. Kozin to Board of Directors (GlobeNewswire)
Mar-01-24 09:06AM	Chimerix, Inc. (NASDAQ:CMRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 11:25PM	Q4 2023 Chimerix Inc Earnings Call (Thomson Reuters StreetEvents) -7.26%
08:11AM	Chimerix Inc Reports Fourth Quarter and Full-Year 2023 Financial Results (GuruFocus.com)
07:27AM	Chimerix: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update (GlobeNewswire)
Feb-27-24 07:00AM	Chimerix to Present at TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-22-24 07:00AM	Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024 (GlobeNewswire)
Dec-29-23 07:00AM	Chimerix Appoints Lisa Decker to Board of Directors (GlobeNewswire)
Dec-04-23 07:00AM	Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer (GlobeNewswire)
Nov-24-23 07:00AM	Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-16-23 07:00AM	Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer (GlobeNewswire)
Nov-03-23 09:12AM	Chimerix, Inc. (NASDAQ:CMRX) Q3 2023 Earnings Call Transcript (Insider Monkey) +8.16%
01:34AM	Q3 2023 Chimerix Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-02-23 10:08AM	Chimerix Inc (CMRX) Reports Q3 2023 Financial Results and Operational Updates (GuruFocus.com)
07:10AM	Chimerix: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update (GlobeNewswire)
Oct-26-23 07:00AM	Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023 (GlobeNewswire)
Oct-23-23 10:08AM	12 Best Penny Stocks to Buy Under $1 (Insider Monkey)
Sep-05-23 07:00AM	Chimerix to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-16-23 10:05AM	Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery" (GlobeNewswire)
Aug-11-23 06:15AM	CMRX Stock Warning! Smart Biotech Investors Will Avoid Chimerix Like the Plague. (InvestorPlace)
Aug-03-23 08:25AM	Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:19AM	Chimerix: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update (GlobeNewswire)
Jul-31-23 07:54AM	10 Best Growth Stocks for the Next 10 Years (Insider Monkey)
Jul-30-23 02:17PM	7 Millionaire-Maker Penny Stocks to Buy Before the Window Closes (InvestorPlace)
Jul-28-23 04:19PM	10 Best Rated Penny Stocks to Buy According to Analysts (Insider Monkey)
Jul-27-23 10:53AM	With 51% ownership, Chimerix, Inc. (NASDAQ:CMRX) boasts of strong institutional backing (Simply Wall St.)
07:00AM	Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023 (GlobeNewswire)
06:00AM	7 Small-Cap Stocks to Buy Before the Breakout (InvestorPlace)
Jul-11-23 08:53PM	Why These 7 Stocks Are the Best Ways to Play Biotech Right Now (InvestorPlace)
Jun-28-23 02:58PM	Durham drugmaker Chimerix names new CEO at pivotal time (American City Business Journals)
Jun-27-23 04:05PM	Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer (GlobeNewswire)
Jun-01-23 08:04PM	7 Deeply Undervalued Growth Stocks to Buy in June (InvestorPlace)
May-31-23 04:01PM	Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference (GlobeNewswire)
May-25-23 07:00AM	Chimerix to Participate in Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) at White House (GlobeNewswire) -5.56%
May-05-23 06:11AM	Chimerix First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-04-23 08:25AM	Chimerix (CMRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:17AM	Chimerix: Q1 Earnings Snapshot (AP Finance)
07:00AM	Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update (GlobeNewswire)
Apr-27-23 07:00AM	Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023 (GlobeNewswire)
Apr-18-23 04:01PM	Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
09:35AM	Chimerix (CMRX) Loses -24.68% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-06-23 05:51AM	Chimerix, Inc. (NASDAQ:CMRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-03-23 06:57PM	The Top 7 Growth Stocks in Biotech (InvestorPlace)
Mar-02-23 10:10PM	Q4 2022 Chimerix Inc Earnings Call (Thomson Reuters StreetEvents) +6.29%

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Melemed Allen S.	CHIEF MEDICAL OFFICER	Feb 13 '25	Sale	4.50	3,065	13,799	152,875	Feb 14 05:50 PM
Andriole Michael T.	PRESIDENT AND CEO	Feb 13 '25	Sale	4.52	7,370	33,282	609,603	Feb 14 05:49 PM
Alrutz Michael Albert	SVP AND GENERAL COUNSEL	Feb 13 '25	Sale	4.52	1,600	7,226	213,596	Feb 14 05:48 PM
Jakeman David	VP OF FINANCE AND ACCOUNTING	Feb 13 '25	Sale	4.53	300	1,360	148,987	Feb 14 05:47 PM
LaSpaluto Michelle	CHIEF FINANCIAL OFFICER	Feb 13 '25	Sale	4.51	2,260	10,196	172,977	Feb 14 05:45 PM
Allen Melemed	Officer	Feb 13 '25	Proposed Sale	4.20	3,500	14,700		Feb 13 03:14 PM
Michael Alrutz	Officer	Feb 13 '25	Proposed Sale	4.20	2,000	8,400		Feb 13 03:02 PM
Michael Andriole	Officer	Feb 13 '25	Proposed Sale	4.20	8,000	33,600		Feb 13 02:51 PM
Michelle LaSpaluto	Officer	Feb 13 '25	Proposed Sale	4.20	2,500	10,500		Feb 13 02:41 PM
Dave Jakeman	Officer	Feb 13 '25	Proposed Sale	4.20	500	2,100		Feb 13 02:27 PM
Jakeman David	VP OF FINANCE AND ACCOUNTING	Jan 30 '25	Sale	4.10	2,800	11,470	149,287	Jan 31 04:40 PM
LaSpaluto Michelle	CHIEF FINANCIAL OFFICER	Jan 30 '25	Sale	4.11	1,015	4,172	175,237	Jan 31 04:39 PM
Andriole Michael T.	PRESIDENT AND CEO	Jan 30 '25	Sale	4.10	2,350	9,636	616,973	Jan 31 04:38 PM
David Jakeman	Officer	Jan 30 '25	Proposed Sale	4.00	3,000	12,000		Jan 30 01:00 PM
Michael Andriole	Officer	Jan 30 '25	Proposed Sale	4.00	2,500	10,000		Jan 30 01:00 PM
Michelle LaSpaluto	Officer	Jan 30 '25	Proposed Sale	4.00	1,100	4,400		Jan 30 01:00 PM
Michael Andriole	Officer	Aug 08 '24	Proposed Sale	0.87	1,500	1,300		Aug 09 01:26 PM
Andriole Michael T.	PRESIDENT AND CEO	Aug 08 '24	Sale	0.83	1,285	1,065	462,453	Aug 09 12:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CMRX

Chimerix Inc

Upgrade your FINVIZ experience